Systematic review: Asian patients with chronic hepatitis C infection

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 10, 2013, Pages 921-936

  Nguyen, L H ^a   Nguyen, M H ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; BMS 790062; BOCEPREVIR; DACLATASVIR; INTERLEUKIN 28B; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; ENDEMIC DISEASE; ETHNIC GROUP; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MASS SCREENING; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THYROID DISEASE; TREATMENT DURATION;

AGE FACTORS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; RISK FACTORS;

EID: 84876471176     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12300     Document Type: Review

References (255)

1. World Health Organization. Hepatitis C Fact Sheet. 2011. Available at: http://www.who.int.mediacentre/factsheets/fs164/en. Accessed January 6, 2012.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
3. Te HS, Jensen DM,. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21.
4. Xia G-L, Liu C-B, Cao H-L, et al,. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol commun 1996; 5: 62-73.
5. U.S. Census Bureau. U.S. Country Quick Facts. Available at: http://www.quickfacts.census.gov/qfd/states/00000.html. Accessed January 6, 2012.
6. Center for Disease Control. CDC DVH-HCV FAQs for Health Professionals. 2011. Available at: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed January 6, 2012.
7. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
8. Center for Disease Control. Control CfD. FASTSTATS-Leading Causes of Death. 2007. Available at: http://www.cdc.gov.nchs/faststats/icod.htm. Accessed January 6, 2012.
9. Verna EC, Brown RS Jr,. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-40.
10. Kao JH, Chen DS,. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 2005; 25: 696-703.
11. Chuang WL, Yu ML, Dai CY, Chang WY,. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006; 49: 99-106.
12. Leung N, Chu C, Tam JS,. Viral hepatitis C in Hong Kong. Intervirology 2006; 49: 23-7.
13. Iwasaki Y, Ikeda H, Araki Y, et al,. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
14. Cheng JT, Hsien C, Sun HE, Tong MJ,. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006; 101: 2737-43.
15. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
16. Ikai I, Arii S, Okazaki M, et al,. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007; 37: 676-91.
17. Chang MH, Chen CJ, Lai MS, et al,. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9.
18. Stuyver L, De Gendt S, Van Geyt C, et al,. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81: 67-74.
19. Norder H, Hammas B, Lee SD, et al,. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 1993; 74: 1341-8.
20. Lindh M, Andersson AS, Gusdal A,. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-93.
21. Nguyen LH, Ha NB, Vutien P, et al. Hepatol Int: Prevalence of hepatitis B virus genotype B in Vietnamese patients with chronic hepatitis B, 2009.
22. Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM,. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health 2010; 100 (Suppl. 1): S118-24.
23. Kallman JB, Tran S, Arsalla A, et al,. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat 2011; 18: 70-6.
24. Kin K, Lin B, Ha N, et al,. High proportion of hepatitis C virus in community Asian American patients with non- liver related complaints. J Clin Gastroenterol 2012; 4: 367-71.
25. Chan GC, Lim W, Yeoh EK,. Prevalence of hepatitis C infection in Hong Kong. J Gastroenterol Hepatol 1992; 7: 117-20.
26. Chen M, Xia S,. A prevalence study on hepatitis C infection in 4,055 healthy children of Beijing. Zhonghua Yu Fang Yi Xue Za Zhi 1999; 33: 158-9.
27. Ding X, Gu H, Zhong ZH, et al,. Molecular epidemiology of hepatitis viruses and genotypic distribution of hepatitis B and C viruses in Harbin, China. Jpn J Infect Dis 2003; 56: 19-22.
28. Fang F, Dong YS, Zhang M,. Hepatitis C virus infection in different groups of children in Wuhan area. J Tongji Med Univ 1993; 13: 239-43.
29. Huang F, Dong Y, Wang Z,. Study on HCV infection and the distribution of HCV genotypes in different populations in Shenyang area. Zhonghua Liu Xing Bing Xue Za Zhi 1998; 19: 134-7.
30. Ito S, Yao DF, Nii C, et al,. Incidence of hepatitis C virus (HCV) antibodies and HCV-RNA in blood donors and patients with liver diseases in the inshore area of the Yangtze River. J Gastroenterol Hepatol 1994; 9: 245-9.
31. Liu F, Chen K, He Z, et al,. Hepatitis C seroprevalence and associated risk factors, Anyang, China. Emerg Infect Dis 2009; 15: 1819-22.
32. Qu JB, Zhang ZW, Shimbo S, et al,. Urban-rural comparison of HBV and HCV infection prevalence in eastern China. Biomed Environ Sci 2000; 13: 243-53.
33. Sherlock CH, Zhuo L, Meng XL, Lin XY, Stiver HG,. Seroepidemiology of hepatitis C virus in Beijing, China. Clin Diagn Virol 1993; 1: 17-22.
34. Sun Y, Zhao Y, Liu X,. Anti-hepatitis C virus screening to prevent hepatitis C virus infection in blood donors. Zhonghua Nei Ke Za Zhi 1995; 34: 696-9.
35. Suzuki K, Mizokami M, Cao K, et al,. Prevalence of hepatitis C virus infection in Nanjing, southern China. Eur J Epidemiol 1997; 13: 511-5.
36. Tao QM, Wang Y, Wang H, et al,. Preliminary report on seroepidemiology of HCV and HBV infection in northern China. Chin Med J (Engl) 1992; 105: 209-11.
37. Wu RR, Mizokami M, Lau JY, et al,. Seroprevalence of hepatitis C virus infection and its genotype in Lanzhou, western China. J Med Virol 1995; 45: 174-8.
38. Wu X,. Investigation on anti-HCV antibody in Shashi District. Zhonghua Liu Xing Bing Xue Za Zhi 1993; 14: 331-3.
39. Zhang M, Sun XD, Mark SD, et al,. Hepatitis C virus infection, Linxian, China. Emerg Infect Dis 2005; 11: 17-21.
40. Zhao SM, Jiang TL, Li RQ, et al,. HCV infection in voluntary donors and its influence on recruitment of donors in Chongqing area. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16: 676-80.
41. Zhang YY, Guo LS, Hao LJ, Hansson BG, Widell A, Nordenfelt E,. Antibodies to hepatitis C virus and hepatitis C virus RNA in Chinese blood donors determined by ELISA, recombinant immunoblot assay and polymerase chain reaction. Chin Med J (Engl) 1993; 106: 171-4.
42. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC,. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106: 148-55.
43. Sun CA, Chen HC, Lu CF, et al,. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999; 59: 290-6.
44. Tsai MC, Kee KM, Chen YD, et al,. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 2007; 22: 92-8.
45. Sun CA, Chen HC, Lu SN, et al,. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001; 65: 30-4.
46. Nelson PK, Mathers BM, Cowie B, et al,. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
47. Department of Health. Surveillance of Viral Hepatitis in Hong Kong-2003 Update Report. 2004. Available at: http://info.gov.hk/hepatitis/doc/hepsurv03. pdf. Accessed January 6, 2012.
48. Yamaguchi K, Kiyokawa H, Machida J, et al,. Seroepidemiology of hepatitis C virus infection in Japan and HCV infection in haemodialysis patients. FEMS Microbiol Rev 1994; 14: 253-8.
49. Tanaka J, Kumagai J, Katayama K, et al,. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
50. Shin HR,. Epidemiology of hepatitis C virus in Korea. Intervirology 2006; 49: 18-22.
51. Ju YH SH, Oh JK, Kim DI, et al,. A seroepidemiological study of hepatitis B and C virus (HBV and HCV) infection in the young population in parts of Busan, Korea. Korean J Prev Med Pub Health 2004; 37: 253-9.
52. Lee JM YH, Jang UK, Kim DJ, et al,. The prevalence of anti-HCV positivity in healthy korean children. Korean J Hepatol 1996; 2: 160-5.
53. Arankalle VA, Chadha MS, Jha J, Amrapurkar DN, Banerjee K,. Prevalence of anti-HCV antibodies in western India. Indian J Med Res 1995; 101: 91-3.
54. Chandrasekaran S, Palaniappan N, Krishnan V, Mohan G, Chandrasekaran N,. Relative prevalence of hepatitis B viral markers and hepatitis C virus antibodies (anti HCV) in Madurai, south India. Indian J Med Sci 2000; 54: 270-3.
55. Das BR, Kundu B, Khandapkar R, Sahni S,. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002; 45: 323-8.
56. Garg S, Mathur DR, Garg DK,. Comparison of seropositivity of HIV, HBV, HCV and syphilis in replacement and voluntary blood donors in western India. Indian J Pathol Microbiol 2001; 44: 409-12.
57. Gupta N, Kumar V, Kaur A,. Seroprevalence of HIV, HBV, HCV and syphilis in voluntary blood donors. Indian J Med Sci 2004; 58: 255-7.
58. Irshad M, Acharya SK,. Status of hepatitis viral markers in patients with acute and chronic liver diseases in northern India. Intervirology 1994; 37: 369-72.
59. Jha J, Banerjee K, Arankalle VA,. A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India. J Viral Hepat 1995; 2: 257-60.
60. Nandi J, Bhawalkar V, Mody H, Elavia A, Desai PK, Banerjee K,. Detection of HIV-1, HBV and HCV antibodies in blood donors from Surat, western India. Vox Sang 1994; 67: 406-7.
61. Nanu A, Sharma SP, Chatterjee K, Jyoti P,. Markers for transfusion-transmissible infections in north Indian voluntary and replacement blood donors: prevalence and trends 1989-1996. Vox Sang 1997; 73: 70-3.
62. Panigrahi AK, Roca J, Acharya SK, Jameel S, Panda SK,. Genotype determination of hepatitis C virus from northern India: identification of a new subtype. J Med Virol 1996; 48: 191-8.
63. Singh S, Prasad R, Mohanty A,. High prevalence of sexually transmitted and blood-borne infections amongst the inmates of a district jail in Northern India. Int J STD AIDS 1999; 10: 475-8.
64. Chowdhury A, Santra A, Chaudhuri S, et al,. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003; 37: 802-9.
65. Jain A, Rana SS, Chakravarty P, et al,. The prevalence of hepatitis C virus antibodies among the voluntary blood donors of New Delhi, India. Eur J Epidemiol 2003; 18: 695-7.
66. Khokhar N, Gill ML, Malik GJ,. General seroprevalence of hepatitis C and hepatitis B virus infections in population. J Coll Physicians Surg Pak 2004; 14: 534-6.
67. Ali SA, Donahue RM, Qureshi H, Vermund SH,. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 2009; 13: 9-19.
68. Umar M, Bushra HT, Ahmad M, et al,. Hepatitis C in Pakistan: a review of available data. Hepatitis monthly 2010; 10: 205-14.
69. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Poovorawan Y,. Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand. Intervirology 2011; 54: 10-6.
70. Thuring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, Grob P,. Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. Southeast Asian J Trop Med Public Health 1993; 24: 239-49.
71. Ol HS, Bjoerkvoll B, Sothy S, et al,. Prevalence of hepatitis B and hepatitis C virus infections in potential blood donors in rural Cambodia. Southeast Asian J Trop Med Public Health 2009; 40: 963-71.
72. Arguillas MO, Domingo EO, Tsuda F, Mayumi M, Suzuki H,. Seroepidemiology of hepatitis C virus infection in the Philippines: a preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines. Gastroenterol Jpn 1991; 26 (Suppl. 3): 170-5.
73. Katayama Y, Barzaga NG, Alipio A, et al,. Genotype analysis of hepatitis C virus among blood donors and inmates in Metro Manila, The Philippines. Microbiol Immunol 1996; 40: 525-9.
74. Yanase Y, Ohida T, Kaneita Y, Agdamag DM, Leano PS, Gill CJ,. The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants. Bull World Health Organ 2007; 85: 131-7.
75. Sulaiman HA, Julitasari, Sie A, et al,. Prevalence of hepatitis B and C viruses in healthy Indonesian blood donors. Trans R Soc Trop Med Hyg 1995; 89: 167-70.
76. Soetjipto, Handajani R, Lusida MI, et al,. Differential prevalence of hepatitis C virus subtypes in healthy blood donors, patients on maintenance hemodialysis, and patients with hepatocellular carcinoma in Surabaya, Indonesia. J Clin Microbiol 1996; 34: 2875-80.
77. Jutavijittum P, Yousukh A, Samountry B, et al,. Seroprevalence of hepatitis B and C virus infections among Lao blood donors. Southeast Asian J Trop Med Public Health 2007; 38: 674-9.
78. Syhavong B, Rasachack B, Smythe L, et al,. The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. Trans R Soc Trop Med Hyg 2010; 104: 475-83.
79. Myo K, San San O, Oo KM, Shimono K, Koide N, Okada S,. Prevalence and factors associated with hepatitis C virus infection among Myanmar blood donors. Acta Med Okayama 2010; 64: 317-21.
80. Lwin AA, Shinji T, Khin M, et al,. Hepatitis C virus genotype distribution in Myanmar: predominance of genotype 6 and existence of new genotype 6 subtype. Hepatol Res 2007; 37: 337-45.
81. Nakai K, Win KM, Oo SS, Arakawa Y, Abe K,. Molecular characteristic-based epidemiology of hepatitis B, C, and E viruses and GB virus C/hepatitis G virus in Myanmar. J Clin Microbiol 2001; 39: 1536-9.
82. Shinji T, Kyaw YY, Gokan K, et al,. Analysis of HCV genotypes from blood donors shows three new HCV type 6 subgroups exist in Myanmar. Acta Med Okayama 2004; 58: 135-42.
83. Kuperan P, Choon AT, Ding SH, Lee G,. Prevalence of antibodies to hepatitis C virus in relation to surrogate markers in a blood donor population of Singapore. Southeast Asian J Trop Med Public Health 1993; 24 (Suppl. 1): 127-9.
84. Wang JE,. A study on the epidemiology of hepatitis C infection among blood donors in Singapore. J Public Health Med 1995; 17: 387-91.
85. Sunanchaikarn S, Theamboonlers A, Chongsrisawat V, et al,. Seroepidemiology and genotypes of hepatitis C virus in Thailand. Asian Pac J Allergy Immunol 2007; 25: 175-82.
86. Ratanasuwan W, Sonji A, Tiengrim S, Techasathit W, Suwanagool S,. Serological survey of viral hepatitis A, B, and C at Thai Central Region and Bangkok: a population base study. Southeast Asian J Trop Med Public Health 2004; 35: 416-20.
87. Theamboonlers A, Chinchai T, Bedi K, Jantarasamee P, Sripontong M, Poovorawan Y,. Molecular characterization of hepatitis C virus (HCV) core region in HCV-infected Thai blood donors. Acta Virol 2002; 46: 169-73.
88. Kanistanon D, Neelamek M, Dharakul T, Songsivilai S,. Genotypic distribution of hepatitis C virus in different regions of Thailand. J Clin Microbiol 1997; 35: 1772-6.
89. Ishida T, Takao S, Settheetham-Ishida W, Tiwawech D,. Prevalence of hepatitis B and C virus infection in rural ethnic populations of Northern Thailand. J Clin Virol 2002; 24: 31-5.
90. Wiwanitkit V,. A note in the high prevalence of anti-HCV seropositivity among hilltribers in Mae Jam District, Northern Thailand. Viral Immunol 2002; 15: 645-6.
91. Nakata S, Song P, Duc DD, et al,. Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam. J Gastroenterol Hepatol 1994; 9: 416-9.
92. Kakumu S, Sato K, Morishita T, et al,. Prevalence of hepatitis B, hepatitis C, and GB virus C/hepatitis G virus infections in liver disease patients and inhabitants in Ho Chi Minh, Vietnam. J Med Virol 1998; 54: 243-8.
93. Tran HT, Ushijima H, Quang VX, et al,. Prevalence of hepatitis virus types B through E and genotypic distribution of HBV and HCV in Ho Chi Minh City, Vietnam. Hepatol Res 2003; 26: 275-80.
94. Clatts MC, Colon-Lopez V, le Giang M, Goldsamt LA,. Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. J Urban Health 2010; 87: 278-91.
95. Vt N, Ml M, Gj D,. Prevalence and risk factors for hepatitis C infection in rural north Vietnam. Hepatol Int 2007; 3: 387-93.
96. DD D, B H, et al,. Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam. Clin Diagn Lab Immunol 1994; 1: 413-8.
97. World Health Organization. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 1997; 72: 341-8.
98. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH,. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 2005; 75: 538-49.
99. Xie Y, Zhao H, Ou WN, Yan J, Du SC, Xu DZ,. The difference in distribution of HCV genotypes between patients infected with HCV by transfusion and non-transfusion routes. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2004; 18: 247-50.
100. Shang H, Zhong P, Liu J, et al,. High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China. PLoS ONE 2010; 5: e10631.
101. Fu Y, Wang Y, Xia W, et al,. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat 2011; 18: 42-52.
102. Zhou Y, Wang X, Mao Q, et al,. Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. J Clin Virol 2009; 46: 230-3.
103. Yue QH, Zhang XQ, Shang Y, et al,. Anti-HCV reactive volunteer blood donors distribution character and genotypes switch in Xi'an, China. Virol J 2010; 7: 186.
104. Chan DP, Lee SS, Lee KC,. The effects of widespread methadone treatment on the molecular epidemiology of hepatitis C virus infection among injection drug users in Hong Kong. J Med Virol 2011; 83: 1187-94.
105. Zhou DX, Tang JW, Chu IM, et al,. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. J Med Virol 2006; 78: 574-81.
106. Prescott LE, Simmonds P, Lai CL, et al,. Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. J Med Virol 1996; 50: 168-75.
107. Abraham R, Ramakrishna B, Balekuduru A, et al,. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease. Indian J Gastroenterol 2009; 28: 53-8.
108. Amarapurkar D,. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15 (Suppl.): E105-10.
109. Amarapurkar D, Dhorda M, Kirpalani A, Amarapurkar A, Kankonkar S,. Prevalence of hepatitis C genotypes in Indian patients and their clinical significance. J Assoc Physicians India 2001; 49: 983-5.
110. Chandra M, Thippavuzzula R, Ramachandra Rao VV, et al,. Genotyping of hepatitis C virus (HCV) in infected patients from South India. Infect Genet Evol 2007; 7: 724-30.
111. Hissar SS, Goyal A, Kumar M, et al,. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006; 78: 452-8.
112. Narahari S, Juwle A, Basak S, Saranath D,. Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort. Infect Genet Evol 2009; 9: 643-5.
113. Raghuraman S, Abraham P, Sridharan G, Daniel HD, Ramakrishna BS, Shaji RV,. HCV genotype 4-an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol 2004; 31: 253-8.
114. Raghuraman S, Shaji RV, Sridharan G, et al,. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. J Clin Virol 2003; 26: 61-9.
115. Saravanan S, Velu V, Kumarasamy N, et al,. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis 2008; 12: 513-8.
116. Singh S, Malhotra V, Sarin SK,. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004; 119: 145-8.
117. Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrison TJ,. Diversity of genotypes of hepatitis C virus in southern India. J Gen Virol 1995; 76: 711-6.
118. Verma V, Chakravarti A, Kar P,. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India. Diagn Microbiol Infect Dis 2008; 61: 408-14.
119. Attaullah S, Khan S, Ali I,. Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J 2011; 8: 433.
120. Yoshii E, Shinzawa H, Saito T, et al,. Molecular epidemiology of hepatitis C virus infection in an area endemic for community-acquired acute hepatitis C. Tohoku J Exp Med 1999; 188: 311-6.
121. Ohno O, Mizokami M, Wu RR, et al,. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-7.
122. Ohno T, Mizokami M, Yamauchi M, et al,. Genotype distribution in Nagoya and new genotype (genotype 3a) in Japanese patients with hepatitis C virus. J Gastroenterol 1995; 30: 209-14.
123. Kim YS AY, Lee HS,. Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotype. J Korean Med Sci 2002; 17: 187-92.
124. Han CJ, Lee HS, Kim HS, Choe JH, Kim CY,. Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases. Korean J Intern Med 1997; 12: 21-7.
125. Lee DS, Sung YC, Whang YS,. Distribution of HCV genotypes among blood donors, patients with chronic liver disease, hepatocellular carcinoma, and patients on maintenance hemodialysis in Korea. J Med Virol 1996; 49: 55-60.
126. Kim CJ, Shin KS, Kim WY, et al,. Genotype distribution and comparison of the putative envelope region of hepatitis C virus from Korean patients. J Med Virol 1995; 46: 380-6.
127. Hubschen JM, Jutavijittum P, Thammavong T, et al,. High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic. Clin Microbiol Infect 2011; 17: E30-4.
128. Pybus OG, Barnes E, Taggart R, et al,. Genetic history of hepatitis C virus in East Asia. J Virol 2009; 83: 1071-82.
129. Nguyen NH, Vutien P, Trinh HN, et al,. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int 2010; 4: 523-9.
130. Song P, Duc DD, Hien B, et al,. Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam. Clin Diagn Lab Immunol 1994; 1: 413-8.
131. Tokita H, Okamoto H, Tsuda F, et al,. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci U S A 1994; 91: 11022-6.
132. Pham DA, Leuangwutiwong P, Jittmittraphap A, et al,. High prevalence of hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol 2009; 27: 153-60.
133. Utama A, Tania NP, Dhenni R, et al,. Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver Int 2010; 30: 1152-60.
134. Utama A, Budiarto BR, Monasari D, et al,. Hepatitis C virus genotype in blood donors and associated liver disease in Indonesia. Intervirology 2008; 51: 410-6.
135. Inoue Y, Sulaiman HA, Matsubayashi K, et al,. Genotypic analysis of hepatitis C virus in blood donors in Indonesia. Am J Trop Med Hyg 2000; 62: 92-8.
136. Tokita H, Okamoto H, Iizuka H, et al,. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996; 77: 293-301.
137. Kageyama S, Agdamag DM, Alesna ET, et al,. Tracking the entry routes of hepatitis C virus as a surrogate of HIV in an HIV-low prevalence country, the Philippines. J Med Virol 2009; 81: 1157-62.
138. Freshwater DA, O'Donnell K, Mutimer DJ,. Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. J Viral Hepat 2008; 15: 115-9.
139. Kaba S, Dutta U, Byth K, et al,. Molecular epidemiology of hepatitis C in Australia. J Gastroenterol Hepatol 1998; 13: 914-20.
140. Dev A, Sundararajan V, Sievert W,. Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition. J Gastroenterol Hepatol 2004; 19: 792-8.
141. Ohto H, Ishii T, Kitazawa J, et al,. Declining hepatitis C virus (HCV) prevalence in pregnant women: impact of anti-HCV screening of donated blood. Transfusion 2010; 50: 693-700.
142. Celona AF, Yu MC, Prakash M, Kuo T, Bonacini M,. Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2004; 2: 459-62.
143. Mele A, Corona R, Tosti ME, et al,. Beauty treatments and risk of parenterally transmitted hepatitis: results from the hepatitis surveillance system in Italy. Scand J Infect Dis 1995; 27: 441-4.
144. Luby SP, Qamruddin K, Shah AA, et al,. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect 1997; 119: 349-56.
145. Habib M, Mohamed MK, Abdel-Aziz F, et al,. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33: 248-53.
146. Chiaramonte M, Stroffolini T, Lorenzoni U, et al,. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol 1996; 24: 129-34.
147. Shin HR, Kim JY, Kim JI, et al,. Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture. Br J Cancer 2002; 87: 314-8.
148. Sood A, Midha V, Sood N, Kaur H, Malhotra V, Awasthi G,. Chronic hepatitis C in northern India-the pathological and clinical spectrum. J Assoc Physicians India 2004; 52: 380-4.
149. Thakral B, Marwaha N, Chawla YK, et al,. Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors. Indian J Med Res 2006; 124: 431-8.
150. Alter HJ,. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 15: 350-3.
151. Gretch DR,. Diagnostic tests for hepatitis C. Hepatology 1997; 26 (Suppl. 1): 43S-7S.
152. Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C,. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 66: 122-9.
153. Lok AS, Chien D, Choo QL, et al,. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497-502.
154. Pereira BJ, Levey AS,. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-99.
155. Pereira BJ, Milford EL, Kirkman RL, et al,. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327: 910-5.
156. Rein DB, Smith BD, Wittenborn JS, et al,. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-70.
157. Germer JJ, Rys PN, Thorvilson JN, Persing DH,. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 2625-30.
158. Bouchardeau F, Cantaloube JF, Chevaliez S, et al,. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-5.
159. Noppornpanth S, Sablon E, De Nys K, et al,. Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5′ untranslated regions. J Clin Microbiol 2006; 44: 3969-74.
160. Verbeeck J, Stanley MJ, Shieh J, et al,. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-6.
161. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ,. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011; 13: 842-8.
162. Vutien P, Nguyen NH, Trinh HN, et al,. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2010; 105: 1110-5.
163. Lawson A,. Trent hepatitis CSG. A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. J Viral Hepat 2011; 18: e270-7.
164. Nguyen MH, Whittemore AS, Garcia RT, et al,. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 820-4.
165. Tanaka K, Sakai H, Hashizume M, Hirohata T,. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998; 89: 1241-50.
166. Ikeda K, Sakai K, Yamamoto R, et al,. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 2003; 13: 776-84.
167. Fattovich G, Ribero ML, Pantalena M, et al,. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat 2001; 8: 206-16.
168. Yip B, Ha N, Kim L, et al,. Ethnic differences in clinical characteristics and treatments of Asian and non-Asian with hepatitis C (HCV)-related hepatocellular carcinoma (HCC). Gastroenterology 2012; 142: S-914-5.
169. Mohamed Ael S, al Karawi MA, Mesa GA,. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997; 44: 1404-6.
170. Chiaramonte M, Stroffolini T, Vian A, et al,. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-7.
171. Benvegnu L, Fattovich G, Noventa F, et al,. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-8.
172. Kaklamani E, Trichopoulos D, Tzonou A, et al,. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 1974-6.
173. Donato F, Boffetta P, Puoti M,. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-54.
174. Crespo J, Lozano JL, de la Cruz F, et al,. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994; 89: 1147-51.
175. Liaw YF,. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 1101-8.
176. Sato S, Fujiyama S, Tanaka M, et al,. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994; 21: 159-66.
177. Ohkawa K, Hayashi N, Yuki N, et al,. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol 1994; 21: 509-14.
178. Chen X, Xuan M, Wu D,. Study of superinfection of HBV and HCV. Zhonghua Liu Xing Bing Xue Za Zhi 1999; 20: 141-3.
179. Xess A, Kumar M, Minz S, Sharma HP, Shahi SK,. Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease. Indian J Pathol Microbiol 2001; 44: 253-5.
180. Coppola RC, Manconi PE, Piro R, Di Martino ML, Masia G,. HCV, HIV, HBV and HDV infections in intravenous drug addicts. Eur J Epidemiol 1994; 10: 279-83.
181. Liaw YF, Lin SM, Sheen IS, Chu CM,. Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection 1991; 19: 250-1.
182. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH,. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993; 67: 5823-32.
183. Sheen IS, Liaw YF, Lin DY, Chu CM,. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994; 170: 358-61.
184. Pontisso P, Ruvoletto MG, Fattovich G, et al,. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-33.
185. Villari D, Pernice M, Spinella S, et al,. Chronic hepatitis in patients with active hepatitis B virus and hepatitis C virus combined infections: a histological study. Am J Gastroenterol 1995; 90: 955-8.
186. Zarski JP, Bohn B, Bastie A, et al,. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
187. Nguyen LH, Ko S, Wong SS, et al,. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011; 53: 1839-45.
188. Coppola N, Pisapia R, Tonziello G, et al,. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther 2008; 13: 307-18.
189. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS,. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-76.
190. Potthoff A, Wedemeyer H, Boecher WO, et al,. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49: 688-94.
191. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G,. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
192. Potthoff A, Deterding K, Trautwein C, Rifai K, Manns MP, Wedemeyer H,. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. Eur J Gastroenterol Hepatol 2007; 19: 906-9.
193. Liu CJ, Chuang WL, Lee CM, et al,. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
194. Hung CH, Lu SN, Wang JH, et al,. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther 2011; 16: 959-68.
195. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
196. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
197. Tillmann HL, Thompson AJ, Patel K, et al,. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92.
198. Hsu CS, Hsu SJ, Chen HC, et al,. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A 2011; 108: 3719-24.
199. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
200. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
201. Ito K, Higami K, Masaki N, et al,. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011; 49: 1853-60.
202. Sinn DH, Kim YJ, Lee ST, et al,. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian Patients. J Gastroenterol Hepatol 2011; 9: 1374-9.
203. Yu ML, Huang CF, Huang JF, et al,. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
204. Clark PJ, Thompson AJ, McHutchison JG,. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106: 38-45.
205. Balagopal A, Thomas DL, Thio CL,. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-76.
206. Swain MG, Lai MY, Shiffman ML, et al,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.
207. Ng V, Saab S,. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 923-30.
208. Russo MW,. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. Expert Rev Gastroenterol Hepatol 2010; 4: 535-9.
209. Morgan TR, Ghany MG, Kim HY, et al,. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
210. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al,. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
211. Veldt BJ, Heathcote EJ, Wedemeyer H, et al,. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
212. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ,. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8.
213. Reddy KR, Hoofnagle JH, Tong MJ, et al,. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-93.
214. Cheng PN, Marcellin P, Bacon B, et al,. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J Viral Hepat 2004; 11: 418-26.
215. Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM,. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol 2011; 45: 720-6.
216. Missiha S, Heathcote J, Arenovich T, Khan K,. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2181-8.
217. Yan KK, Guirgis M, Dinh T, et al,. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14: 3416-20.
218. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
219. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
220. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
221. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
222. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
223. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
224. Kuboki M, Iino S, Okuno T, et al,. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22: 645-52.
225. Lee HJ, Eun JR, Choi JW, Kim KO, Moon HJ,. Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C. Korean J Hepatol 2008; 14: 46-57.
226. Liu CH, Liu CJ, Lin CL, et al,. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-9.
227. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC,. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.
228. Yu ML, Dai CY, Huang JF, Chuang WL,. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Hepatology 2008; 48: 1019-20.
229. Ghany MG, Strader DB, Thomas DL, Seeff LB,. American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
230. Zeuzem S, Hultcrantz R, Bourliere M, et al,. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
231. von Wagner M, Huber M, Berg T, et al,. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
232. Bonny C, Fontaine H, Poynard T, et al,. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006; 24: 593-600.
233. Antaki N, Hermes A, Hadad M, et al,. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008; 15: 383-6.
234. Alfaleh FZ, Hadad Q, Khuroo MS, et al,. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568-74.
235. Hasan F, Asker H, Al-Khaldi J, et al,. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-7.
236. Shobokshi O, Serebour F, Skakni L,. Efficacy of pegylated (40 KDA) IFN alfa-2a (PEGASYS) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. J Hepatol 2002; 58: 129.
237. Antaki N, Craxi A, Kamal S, et al,. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-55.
238. Benhamou Y, Moussalli J, Ratziu V, et al,. Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 4 hepatitis C patients: final results of study C210. Hepatology 2010; 52 (S1): 719A.
239. Reesink HW, Zeuzem S, Weegink CJ, et al,. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
240. Hassanein T, Nelson D, Lawitz E, et al,. PSI-7977 with PEG/RBV Elicits Rapid Declines in HCV RNA in Patients with HCV GT-4 and GT-6. HEPDart, December 4-8, 2011 (Kauai, H1). Available at: http://www.natap.org/2011/hepDART/hepDART- 01.htm. Accessed January 6, 2012.
241. Flisiak R, Feinman SV, Jablkowski M, et al,. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 1460-8.
242. Hezode C HG, Ghesquiere W,. Daclatasvir (DCV;BMS-790052), and NS5A replication complex inhibitor, combined with peginterferon-alfa-2b and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2B command-1 study interim week 24 results. Hepatology 2011; 54: 127A.
243. Hezode C HG, Ghesquiere W,. Daclatasvir (BMS-790052), A NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results. Hepatol Int 2012; 6: 167.
244. Nguyen NH, VuTien P, Garcia RT, et al,. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010; 17: 691-7.
245. Tsang OT, Zee JS, Chan JM, et al,. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol 2010; 25: 766-71.
246. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB,. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 1131-5.
247. Lam KD, Trinh HN, Do ST, et al,. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52: 1573-80.
248. Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K,. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol 2012; 56: 1012-8.
249. Chang CH, Chen KY, Lai MY, Chan KA,. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1623-32.
250. Dalgard O, Bjoro K, Hellum K, et al,. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400-6.
251. Jamil KM, Leedman PJ, Kontorinis N, et al,. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 1017-23.
252. Sievert W, Altraif I, Razavi HA, et al,. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 (Suppl 2): 61-80.
253. Lee CM, Lu SN, Hung CH, et al,. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg 2006; 100: 767-74.
254. Yu ML, Chuang WL, Chen SC, et al,. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001; 65: 58-65.
255. Yu ML, Chuang WL, Lu SN, et al,. The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan. Kaohsiung J Med Sci 1996; 12: 605-12.